RxDoctor Payments Data

Jean Rony Jean Mary, MD

Family Medicine · Fort Lauderdale, FLNPI 1346317088

Payments from drug & device makers

$5,246in general payments, 2019–2025

Across 246 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • Vanda Pharmaceuticals Inc.$1K
  • Johnson & Johnson$429
  • Lundbeck LLC$356
  • Otsuka America Pharmaceutical, Inc.$233
  • Boston Scientific$207
  • plus $311 from 8 others

What the payments were for

  • Food & beverage$4,87093%
  • Education$3767%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,246 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$116,254
Medicare patients
83
Services billed
1,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine47$299,999
BiktarvyBictegrav/Emtricit/Tenofov Ala12$47,007
FanaptIloperidone18$34,145
Ziprasidone Hcl191$28,311
Chlorpromazine Hcl48$27,496
RexultiBrexpiprazole12$17,326
NamzaricMemantine Hcl/Donepezil Hcl22$12,523
Divalproex Sodium ErDivalproex Sodium90$11,417
Divalproex Sodium169$9,948
TrintellixVortioxetine Hydrobromide18$8,592
Quetiapine Fumarate283$8,033
LinzessLinaclotide12$7,109
TradjentaLinagliptin12$6,844
Olanzapine223$5,968
BelsomraSuvorexant12$5,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$2,554$299,99947 claims
GileadBiktarvy$89$47,00712 claims
Vanda Pharmaceuticals Inc.Fanapt$1,155$34,14518 claims
Otsuka America Pharmaceutical, Inc.Rexulti$233$17,32612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →